Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aumolertinib→

Aumolertinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1899921-05-1
Molecular formula
C30H35N7O2
Molecular weight
525.6 g/mol
Drug class
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitortargeted antineoplastic
Mechanism of action
Selectively and irreversibly inhibits mutant EGFR, including sensitising mutations and T790M resistance mutation, reducing downstream oncogenic signalling in EGFR-mutated tumour cells.
Indications / reported uses
  • Treatment of locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) in China and other jurisdictions where aumolertinib is authorised; treatment line and mutation criteria are product- and jurisdiction-specific

Sources: PubMed — Aumolertinib clinical pharmacology and NSCLC · NLM MeSH — Aumolertinib · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aumolertinib Environmental Risk Assessment (ERA) (the Aumolertinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.